Clinical efficacy and safety of carbon dioxide laser combined with plasma in the treatment of proliferative dermatosis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400084124

Enrollment

Unknown

Registered

2024-05-10

Start date

2024-01-31

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperproliferative skin disease

Interventions

Experimental group:cold atmospheric plasma treatment

control group: regional treatment of surgery

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with skin proliferative diseases, and the traditional treatment effect is not good or can not tolerate the adverse reactions caused by traditional treatment (2) The age range is 18-65 years old, and the gender ratio is not limited (3) inpatient or outpatient patients with good compliance; (4) Voluntarily enroll in clinical trials and sign informed consent; (5) meet the diagnostic criteria for the corresponding skin trauma/disease; (6) After two attending or above doctors jointly diagnosed.

Exclusion criteria

Exclusion criteria: (1) Patients with severe infection wounds need systemic monitoring; (2) Patients with local or total foot gangrene and septicemia; (3) Patients with other acute diseases requiring clinical intervention; (4) Severe hepatic and renal insufficiency (ALT> more than 2.5 times the normal high line, serum creatinine >250µmol/L or GFR=45mL/min/1.73m2); Heart failure; A history of cerebral hemorrhage or cerebral infarction with residual limb paralysis, malignant tumor or mental illness; (5) Severely poor blood glucose control (FPG>13.0mmol/L, HbA1c>15%); Diabetic ketoacidosis, hyperosmolar coma and other acute diabetic complications; (6) long-term use of steroid hormones and immunosuppressants; (7) Patients with cancerous or tuberculous ulcers, leprosy ulcers, and syphilis ulcers; (8) Patients participating in clinical research for other diseases; (9) Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Wound healing rate;healing rate;improvement rate;cure time;Improvement time;	—

Secondary

Measure	Time frame
cicatrix;pain; pruritus;	—

Countries

China

Contacts

Public ContactYANG CHUNJUN

The second Affiliated Hospital of Anhui Medical University

yangchunjun9@163.com+86 139 6668 1316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026